JPRN-jRCT2031260191 CMG1A46 B-cell lymphoma refractory Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Turn a newly registered trial into a decision-ready clinical landscape. This report examines JPRN-jRCT2031260191 using PatSnap Clinical Trials MCP for protocol design and endpoint evidence, with Drug & Asset MCP and Company & Deal Intelligence MCP used as the companion asset and sponsor enrichment workflow. Explore PatSnap MCP Servers to reproduce the research sequence inside an AI workflow.
MCP evidence snapshot: 7 August 2026. Trial records, recruitment status and projected dates can change after the snapshot and should be rechecked before operational decisions.
Why JPRN-jRCT2031260191 is a hot trial to watch
B-cell lymphoma refractory is being segmented by mechanism, treatment setting, geography and endpoint architecture. JPRN-jRCT2031260191 is notable because it evaluates CMG1A46 in a Phase 1/2 design sponsored by GlaxoSmithKline KK. The main development question is whether the protocol can translate its rationale into a clinically interpretable and operationally credible readout.
Trial landscape snapshot
| Field | Indexed detail |
|---|---|
| Registration | JPRN-jRCT2031260191 |
| Official title | A Phase 1/2 Open-label, Multi-center Study to Evaluate the Safety and Clinical Activity of GSK5926371 in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (B NHL) |
| Phase / status | Phase 1/2 / 募集前 |
| Intervention | CMG1A46 |
| Sponsor | GlaxoSmithKline KK |
| Geography | United States, Australia, Japan, France, Italy, Finland, Spain, Canada, Germany |
| Enrollment | [object Object] |
| Primary endpoint | DLT観察期間における用量別のDLT発現率 有害事象／重篤な有害事象の発現率及び重症度 |
| Endpoint time frame | Not reported |
| Primary completion / readout proxy | [object Object] |
Protocol design and endpoint interpretation
The indexed record describes a Phase 1/2 study of CMG1A46 in B-cell lymphoma refractory.
Allocation is Non-Randomized, masking is Open Label, and the intervention model is Single Group Assignment. Planned enrollment of [object Object] participants across United States, Australia, Japan, France, Italy, Finland, Spain, Canada, Germany shapes statistical precision, execution risk and external validity. Interpretation should account for baseline risk, prior therapy, assessment schedule, missing-data handling and clinical relevance—not only statistical significance.
- DLT観察期間における用量別のDLT発現率 有害事象／重篤な有害事象の発現率及び重症度 (time frame not reported)
- Incidence of DLTs per dose level in the DLT observation period. Incidence and severity of AEs/SAEs. (time frame not reported)
Readout outlook and evidence gap
The current protocol points to [object Object] as the best available readout proxy. Because this is an active or newly posted study, a trial-specific result citation is not included until a normalized clinical-trial-result record becomes available. That gap is itself operationally important: teams should monitor first result indexing, conference abstracts, protocol amendments and changes to the primary-completion date.
Build a living trial monitor: connect to PatSnap MCP Servers and track recruitment, endpoint revisions, projected readouts and new result records without manually reconciling separate databases.
Asset and sponsor context
Drug & Asset MCP profile: CMG1A46 is indexed as No normalized modality returned, with target No normalized target returned, mechanism No normalized mechanism returned, and global highest development status No normalized global status returned.
Company & Deal Intelligence MCP profile: GlaxoSmithKline KK is resolved to a normalized organization record in Japan. The organization workflow adds identity, location, portfolio and partnering context where available.
The sponsor profile matters because scientific rationale alone does not determine development value. Manufacturing readiness, portfolio fit, geographic reach, partnering capacity and the ability to fund confirmatory development can determine whether a positive signal becomes a competitive asset.
White space around this program
- Sharper patient selection: prospective biomarker or phenotype definitions that identify who is most likely to benefit.
- Clinically interpretable endpoints: outcomes connecting activity with function, symptoms, survival or treatment burden.
- Comparator relevance: evidence against the most decision-relevant contemporary standard of care.
- Broader external validity: evidence across additional geographies, demographic groups and real-world settings.
- Operational differentiation: a development path that closes the readout gap without sacrificing safety or durability.
What to monitor next
Monitor recruitment, enrollment changes, protocol amendments, endpoint hierarchy, primary-completion timing, first result indexing, asset ownership and sponsor partnerships. A change in endpoint, population or ownership can alter the probability of success before a headline data release.
Bottom line
JPRN-jRCT2031260191 provides a focused lens on B-cell lymphoma refractory development. Its value will be determined by whether CMG1A46 can convert the current Phase 1/2 design into evidence that is clinically meaningful, operationally credible and differentiated from competing programs.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and combine Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable building blocks for trial monitoring and SEO-ready clinical reports.
